EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TRIM33 Is a Co-Regulator of Estrogen Receptor Alpha

Bianca A Romo, Barbara Karakyriakou iD, Lauren Cressey, Brooke L Brauer, Huijuan Yang, Alexa Warren, Anneka L Johnson, Arminja N Kettenbach, Todd W Miller

Cancers · 20.02.2024 · 16 (5) · 845

DOI: 10.3390/cancers16050845 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 20.02.2024. Verfasst von Bianca A Romo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Lebanon, NH 03755, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Estrogen receptor alpha (ER)-positive breast cancer is responsible for over 60% of breast cancer cases in the U.S. Among patients diagnosed with early-stage ER+ disease, 1/3 will experience recurrence despite treatment with adjuvant endocrine therapy. ER is a nuclear hormone receptor responsible for estrogen-driven tumor growth. ER transcriptional activity is modulated by interactions with coregulators. Dysregulation of the levels of these coregulators is involved in the development of endocrine resistance. To identify ER interactors that modulate transcriptional activity in breast cancer, we utilized biotin ligase proximity profiling of ER interactomes. Mass spectrometry analysis revealed tripartite motif containing 33 (TRIM33) as an estrogen-dependent interactor of ER. shRNA knockdown showed that TRIM33 promoted ER transcriptional activity and estrogen-induced cell growth. Despite its known role as an E3 ubiquitin ligase, TRIM33 increased the stability of endogenous ER in breast cancer cells. TRIM33 offers a novel target for inhibiting estrogen-induced cancer cell growth, particularly in cases of endocrine resistance driven by ER (ESR1) gene amplification or overexpression.

Schlagwörter

Stichwörter der Autor:innen

ER+ breast cancerestradiolhormone signalingprotein stabilitytranscription cofactor

Autor:innen und Institutionen

  • Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Lebanon, NH 03755, USA.
  • Department of Biochemistry and Cell Biology, Geisel School of Medicine at Dartmouth, Lebanon, NH 03755, USA.
  • Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
  • Department of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.

ORCID-Profile: Barbara Karakyriakou

Förderung

  • NCI NIH HHS
  • NIH HHS
  • NIGMS NIH HHS
  • Susan G. Komen
  • NIH
  • Center for Quantitative Biology at Dartmouth
  • Dartmouth College Cancer Center

Zitieren

APA

Romo, B. A., Karakyriakou, B., Cressey, L., Brauer, B. L., Yang, H., Warren, A., Johnson, A. L., Kettenbach, A. N., & Miller, T. W. (2024). TRIM33 Is a Co-Regulator of Estrogen Receptor Alpha. Cancers, 16(5), 845. https://doi.org/10.3390/cancers16050845

Vancouver

Romo BA, Karakyriakou B, Cressey L, Brauer BL, Yang H, Warren A, et al. TRIM33 Is a Co-Regulator of Estrogen Receptor Alpha. Cancers. 2024;16(5):845. doi:10.3390/cancers16050845

BibTeX
@article{Romo2024,
  author = {Romo, Bianca A and Karakyriakou, Barbara and Cressey, Lauren and Brauer, Brooke L and Yang, Huijuan and Warren, Alexa and Johnson, Anneka L and Kettenbach, Arminja N and Miller, Todd W},
  title = {TRIM33 Is a Co-Regulator of Estrogen Receptor Alpha},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {5},
  pages = {845},
  doi = {10.3390/cancers16050845}
}
Kostenlos starten →